利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.03 秒)

    Meltrins
    1.
    发明授权
    Meltrins 失效

    公开(公告)号：US07060791B2

    公开(公告)日：2006-06-13

    申请号：US09983531

    申请日：2001-10-24

    申请人： Atsuko Fujisawa ,  Toru Yamakawa ,  Kamon Shirakawa ,  Chitose Orii ,  Naoki Ogawa

    发明人： Atsuko Fujisawa ,  Toru Yamakawa ,  Kamon Shirakawa ,  Chitose Orii ,  Naoki Ogawa

    IPC分类号： A61K38/04

    CPC分类号： C12N9/6489 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/705 ,  C07K16/40 ,  C07K2317/76

    摘要： The purpose of the present invention is to provide a novel protein involved in adhesion and fusion between myoblasts in the course of the formation of byotube. The present invention relates to Meltrins, which a membrane protein having fusion, adhesion and aggregation activity of cells, especially myoblast; and to polypeptides of their domains, DNAs encoding them, antisense RNA for these DNAs, various antibodies to Meltrins and the polypeptides of their domains, expression vectors containing these DNAs, and transformants by these vectors; as well as to the process for producing Meltrins and the polypeptides of their domains using those transformants and medical compositions comprising Meltrins or antagonist against them as an effective ingredient.

    MELTRINS
    2.
    发明申请
    MELTRINS 失效
    墨西哥

    公开(公告)号：US20060247164A1

    公开(公告)日：2006-11-02

    申请号：US11276738

    申请日：2006-03-13

    申请人： Atsuko Fujisawa ,  Toru Yamakawa ,  Kamon Shirakawa ,  Chitose Orii ,  Naoki Ogawa

    发明人： Atsuko Fujisawa ,  Toru Yamakawa ,  Kamon Shirakawa ,  Chitose Orii ,  Naoki Ogawa

    IPC分类号： A61K38/17 ,  C07K14/705 ,  C07K16/18

    CPC分类号： C12N9/6489 ,  A61K38/00 ,  A61K2039/505 ,  C07K14/705 ,  C07K16/40 ,  C07K2317/76

    摘要： The purpose of the present invention is to provide a novel protein involved in adhesion and fusion between myoblasts in the course of the formation of byotube. The present invention relates to Meltrins, which a membrane protein having fusion, adhesion and aggregation activity of cells, especially myoblast; and to polypeptides of their domains, DNAs encoding them, antisense RNA for these DNAs, various antibodies to Meltrins and the polypeptides of their domains, expression vectors containing these DNAs, and transformants by these vectors; as well as to the process for producing Meltrins and the polypeptides of their domains using those transformants and medical compositions comprising Meltrins or antagonist against them as an effective ingredient.

    摘要翻译： 本发明的目的是提供一种新颖的蛋白质，其涉及在成骨细胞形成过程中成肌细胞之间的粘附和融合。 本发明涉及一种蛋白质，其具有细胞，特别是成肌细胞的融合，粘附和聚集活性的膜蛋白; 和其结构域的多肽，编码它们的DNA，这些DNA的反义RNA，对于Meltrins的各种抗体及其结构域的多肽，含有这些DNA的表达载体和通过这些载体的转化体; 以及使用这些转化体和包含Meltrins或其拮抗剂的药物组合物作为有效成分来生产Meltrins及其结构域的多肽的方法。

    Monoclonal antibody against platelet membrane glycoprotein VI
    4.
    发明申请
    Monoclonal antibody against platelet membrane glycoprotein VI 审中-公开
    针对血小板膜糖蛋白的单克隆抗体VI

    公开(公告)号：US20070025992A1

    公开(公告)日：2007-02-01

    申请号：US10564745

    申请日：2004-07-20

    申请人： Hiroshi Takayama ,  Kamon Shirakawa ,  Toru Yamakawa ,  Tetsushi Kawahara

    发明人： Hiroshi Takayama ,  Kamon Shirakawa ,  Toru Yamakawa ,  Tetsushi Kawahara

    IPC分类号： A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C07K16/18 ,  C12N5/06

    CPC分类号： C07K16/2803 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2319/30

    摘要： The present invention provides a human antibody or an active-fragment thereof that specifically binds to human platelet membrane glycoprotein VI and does not induce a human platelet aggregation independently; a cell that produces the antibody or its active-fragment; a pharmaceutical composition that comprises the antibody or its active-fragment as an active ingredient, and so on. The above-mentioned cell can be obtained for example, as follows: a peripheral-blood-lymphocyte of the human that produces an autologous antibody to GPVI is activated by in vitro immunization under specific conditions; a hybridoma with mouse myeloma cell is prepared; and then the hybridoma that produces a monoclonal antibody, which has a binding capacity to GPVI and has an activity that suppresses collagen-mediated agglutinability of the human platelet is selected.

    摘要翻译： 本发明提供了特异性结合人血小板膜糖蛋白VI并且不独立诱导人血小板聚集的人抗体或其活性片段， 产生抗体或其活性片段的细胞; 包含抗体或其活性片段作为活性成分的药物组合物等。 上述细胞可以例如如下获得：产生GPVI自体抗体的人的外周血淋巴细胞通过在特定条件下的体外免疫而被活化; 制备具有小鼠骨髓瘤细胞的杂交瘤; 然后选择产生具有GPVI结合能力并具有抑制人血小板的胶原介导的凝集能力的活性的单克隆抗体的杂交瘤。

    DIAGNOSIS OF RESPIRATORY TRACT INFECTIOUS DISEASES USING URINE SPECIMENS
    5.
    发明申请
    DIAGNOSIS OF RESPIRATORY TRACT INFECTIOUS DISEASES USING URINE SPECIMENS 有权
    使用尿液样本诊断呼吸道感染性疾病

    公开(公告)号：US20140171359A1

    公开(公告)日：2014-06-19

    申请号：US14118302

    申请日：2012-05-18

    申请人： Kamon Shirakawa

    发明人： Kamon Shirakawa

    IPC分类号： G01N33/569 ,  A61K38/16 ,  A61K31/665 ,  A61K31/43 ,  A61K31/407

    CPC分类号： G01N33/56911 ,  A61K31/407 ,  A61K31/43 ,  A61K31/65 ,  A61K31/665 ,  A61K31/7008 ,  A61K31/7028 ,  A61K38/02 ,  A61K38/16 ,  A61K45/00 ,  G01N2333/70596 ,  G01N2800/12 ,  G01N2800/52

    摘要： Provided are a method for detecting respiratory infection associated with bacterial infection, a method for selecting patients with respiratory infection to receive an antibiotic, and a method for determining the timing for ending administration of an antibiotic to a patient with respiratory infection receiving the antibiotic, wherein said methods are characterized in that they are able to appropriately select patients with respiratory infection to whom the antibiotic is to be administered, to adjust the administration period of the antibiotic, and to treat respiratory infection associated with bacterial infection, and in that a measured value of sCD14-ST in urine is used as an indication.

    摘要翻译： 提供了一种检测与细菌感染相关的呼吸道感染的方法，选择呼吸道感染患者以接受抗生素的方法，以及用于确定终止对接受抗生素的呼吸道感染的患者施用抗生素的时间的方法，其中 所述方法的特征在于它们能够适当选择要施用抗生素的呼吸道感染患者，以调节抗生素的施用时间，并治疗与细菌感染相关的呼吸道感染，并且测量值 使用尿液中的sCD14-ST作为指标。

    Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding
    9.
    发明授权
    Anti-CD14 monoclonal antibody having effect of inhibiting CD14/TLR binding 失效
    具有抑制CD14 / TLR结合作用的抗CD14单克隆抗体

    公开(公告)号：US07264967B2

    公开(公告)日：2007-09-04

    申请号：US10432236

    申请日：2001-09-28

    申请人： Shoji Furusako ,  Kamon Shirakawa ,  Sadao Mori

    发明人： Shoji Furusako ,  Kamon Shirakawa ,  Sadao Mori

    IPC分类号： C12N5/06

    CPC分类号： C07K16/2896 ,  A61K2039/505 ,  C07K2317/34 ,  G01N2500/00

    摘要： The present invention provides an antibody which specifically recognizes an epitope containing a part of a domain based on a finding that the domain ranging from the 269- to 315-positions of human CD14 represented by SEQ ID NO:1 is a site capable of interacting with another protein, an antibodies provided. This antibody can inhibit the interaction between human CD14 and another protein and thus suppress cell activation. And also, the present invention provides hybridomas producing the above antibody or its fragment; a peptide containing the amino acids in the domain as specified above; a method of constructing an antibody with the use of this peptide as an immunogen; and a method of screening a medicament for sepsis involving the step of bringing a test substance into contact with CD14 and TLR.

    摘要翻译： 本发明提供了一种抗体，其特异性识别含有部分结构域的表位，基于以下发现：由SEQ ID NO：1表示的人CD14的269位至315位的结构域是能够与 另一种蛋白质，提供抗体。 该抗体可抑制人CD14与另一种蛋白质之间的相互作用，从而抑制细胞活化。 而且，本发明提供了产生上述抗体或其片段的杂交瘤; 含有如上所述的结构域中的氨基酸的肽; 使用该肽作为免疫原构建抗体的方法; 以及筛选涉及使测试物质与CD14和TLR接触的步骤的败血症药物的方法。